After more than 20 years in the industry, Ivana Magovčević-Liebisch had done it all — except build a company from scratch. Then Bruce Booth at Atlas Venture mentioned a couple of TREM2 assets he was trying to snag from Amgen’s old neuroscience pipeline.
Local life sciences investor Atlas Venture is continuing its push into RNA therapies with a new company: Remix Therapeutics.
Launching a clinical trial for a drug intended to treat severe asthma during a respiratory pandemic — particularly one that seems to hit people with some types of asthma particularly hard — could be a risky move.
Biotech punches way above its weight-class, and that’s never been more apparent than in this pandemic and the race for a COVID vaccine.
Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, announced today that Rajesh (Raj) Devraj, PhD, is joining the firm as a venture partner. Devraj will be working with the Atlas team to identify and execute upon compelling opportunities for new biotechnology company creation.